Biocardia Inc Total Assets
Biocardia Inc total assets. Based on the latest financial reports, Biocardia Inc (BCDA) holds total assets worth $4.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BCDA company net worth for the company's overall valuation and market capitalisation.
Total Assets of Biocardia Inc (1995–2025)
Total assets of Biocardia Inc from 1995 to 2025. This chart illustrates how Biocardia Inc's total assets have evolved over time, based on quarterly financial data. See latest Biocardia Inc stock price today for real-time trading data and today's change.
Biocardia Inc - Asset Composition Analysis
Biocardia Inc Total Assets Breakdown (December 2025)
Biocardia Inc total assets breakdown as of December 2025. Biocardia Inc's total assets of $4.75 Million consist of 80.1% current assets and 20.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 73.1% |
| Accounts Receivable | $20.00K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Biocardia Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BCDA net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biocardia Inc's current assets represent 80.1% of total assets in 2025, an increase from 58.2% in 1995.
- Cash Position: Cash and equivalents constituted 73.1% of total assets in 2025, up from 3.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Biocardia Inc Competitors by Total Assets
Key competitors of Biocardia Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Biocardia Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 0.33 | 4.34 |
| Quick Ratio | 2.09 | 0.33 | 4.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.24 Million | $-2.44 Million | $13.09 Million |
Biocardia Inc - Advanced Valuation Insights
This section examines the relationship between Biocardia Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.89 |
| Latest Market Cap to Assets Ratio | 4.09 |
| Asset Growth Rate (YoY) | -8.4% |
| Total Assets | $3.41 Million |
| Market Capitalization | $13.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biocardia Inc's assets at a significant premium (4.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biocardia Inc's assets decreased by 8.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biocardia Inc (1995–2025)
The table below shows the annual total assets of Biocardia Inc from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.41 Million | -8.35% |
| 2024-12-31 | $3.72 Million | +24.67% |
| 2023-12-31 | $2.99 Million | -69.50% |
| 2022-12-31 | $9.79 Million | -37.70% |
| 2021-12-31 | $15.72 Million | -32.90% |
| 2020-12-31 | $23.42 Million | +205.08% |
| 2019-12-31 | $7.68 Million | +19.65% |
| 2018-12-31 | $6.42 Million | -52.60% |
| 2017-12-31 | $13.54 Million | -38.69% |
| 2016-12-31 | $22.08 Million | +59.14% |
| 2015-12-31 | $13.88 Million | +2.44% |
| 2014-12-31 | $13.54 Million | +1.63% |
| 2013-12-31 | $13.33 Million | +0.20% |
| 2012-12-31 | $13.30 Million | -3.15% |
| 2011-12-31 | $13.73 Million | +152.70% |
| 2010-12-31 | $5.43 Million | -65.13% |
| 2009-12-31 | $15.59 Million | +35.85% |
| 2008-12-31 | $11.47 Million | +13071.85% |
| 2007-12-31 | $87.11K | -50.20% |
| 2006-12-31 | $174.92K | -80.51% |
| 2005-12-31 | $897.27K | -47.41% |
| 2004-12-31 | $1.71 Million | -35.43% |
| 2003-12-31 | $2.64 Million | -10.78% |
| 2002-12-31 | $2.96 Million | -29.28% |
| 2001-12-31 | $4.19 Million | -43.63% |
| 2000-12-31 | $7.43 Million | +132.15% |
| 1999-12-31 | $3.20 Million | -21.95% |
| 1998-12-31 | $4.10 Million | -12.77% |
| 1997-12-31 | $4.70 Million | 0.00% |
| 1996-12-31 | $4.70 Million | +400.54% |
| 1995-12-31 | $938.99K | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more